Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Is clozapine more effective than other second-generation antipsychotics for people with resistant schizophrenia?
METHODS
Design:
Randomised controlled trial.
Allocation:
Concealed.
Blinding:
Single blind (assessors blinded).
Follow-up period:
Twelve months.
Setting:
Five centres, UK; time period not stated.
Patients:
136 adults (18–65 years old) with DSM-IV schizophrenia, schizoaffective or delusional disorder and poor clinical response to at least two other treatments. Exclusions: neuroleptic malignant disorder, substance misuse or medical disorder responsible for psychotic symptoms.
Intervention:
Clozapine (end dose range 100–600 mg/day; mean end dose 333 mg/day) or other second-generation antipsychotic (amisulpride 600–800 mg/day (mean 683 mg/day), olanzapine 10–30 mg/day …
Footnotes
For correspondence: Shôn W Lewis, University of Manchester, Manchester, UK; shon.lewis{at}manchester.ac.uk
Source of funding: NHS Technology Assessment Program, UK.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.